bexarotene has been researched along with Apoplexy in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amantea, D; Bagetta, G; Certo, M; Endo, Y; Ohta, K; Sakurada, S | 1 |
| Dhungana, H; Goldsteins, G; Huuskonen, MT; Kanninen, KM; Keksa-Goldsteine, V; Koistinaho, J; Koponen, J; Korhonen, P; Landreth, G; Lemarchant, S; Loppi, S; Malm, T; Pollari, E; Takashima, A; Valonen, P; Wojciechowski, S | 1 |
| Stein, A | 1 |
3 other study(ies) available for bexarotene and Apoplexy
| Article | Year |
|---|---|
Activation of RXR/PPARĪ³ underlies neuroprotection by bexarotene in ischemic stroke.
Topics: Animals; Bexarotene; Brain Ischemia; Male; Mice; Mice, Inbred C57BL; Neuroprotection; Neuroprotective Agents; PPAR gamma; Retinoid X Receptors; Stroke; Tetrahydronaphthalenes | 2015 |
Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy.
Topics: Aging; Animals; Autophagy; Bexarotene; Mice; Mice, Transgenic; Neuroprotective Agents; Stroke; Tauopathies; Tetrahydronaphthalenes; Thromboembolism | 2016 |
Bexarotene monotherapy for patients with refractory early stage mycosis fungoides.
Topics: Aged, 80 and over; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Mycosis Fungoides; Neoplasm Staging; Skin Neoplasms; Stroke; Tetrahydronaphthalenes | 2008 |